Plau (plasminogen activator, urokinase) - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Gene: Plau (plasminogen activator, urokinase) Rattus norvegicus
Analyze
Symbol: Plau
Name: plasminogen activator, urokinase
RGD ID: 3343
Description: Enables peptidase activity. Involved in several processes, including cellular response to hepatocyte growth factor stimulus; cellular response to staurosporine; and positive regulation of ovulation. Located in extracellular space and membrane. Used to study several diseases, including alcoholic liver cirrhosis; lung disease (multiple); sciatic neuropathy; status epilepticus; and transient cerebral ischemia. Biomarker of brain disease (multiple); end stage renal disease; myocardial infarction; sciatic neuropathy; and thrombosis. Human ortholog(s) of this gene implicated in several diseases, including Alzheimer's disease (multiple); Quebec platelet disorder; end stage renal disease; lung disease (multiple); and mitral valve prolapse. Orthologous to human PLAU (plasminogen activator, urokinase); PARTICIPATES IN fibrinolysis pathway; fibroblast growth factor signaling pathway; coagulation cascade pathway; INTERACTS WITH (+)-catechin; 1-naphthyl isothiocyanate; 2,3,7,8-tetrachlorodibenzodioxine.
Type: protein-coding
RefSeq Status: PROVISIONAL
Previously known as: MGC124931; U-plasminogen activator; uPA; UPAM; Urinary plasminogen activator urokinase; Urinary plasminogen activator, urokinase; urokinase plasminogen activator; urokinase-type plasminogen activator
RGD Orthologs
Human
Mouse
Chinchilla
Bonobo
Dog
Squirrel
Pig
Green Monkey
Naked Mole-Rat
Alliance Genes
More Info more info ...
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Position:
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
mRatBN7.2153,456,230 - 3,462,732 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl153,456,232 - 3,462,775 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx153,466,414 - 3,472,916 (-)NCBIRnor_SHR
UTH_Rnor_SHRSP_BbbUtx_1.0154,852,895 - 4,859,397 (-)NCBIRnor_SHRSP
UTH_Rnor_WKY_Bbb_1.0153,465,220 - 3,471,722 (-)NCBIRnor_WKY
Rnor_6.0153,644,296 - 3,650,765 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl153,644,769 - 3,650,819 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.0153,621,057 - 3,627,467 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.4153,680,072 - 3,686,232 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.1153,680,073 - 3,686,275 (-)NCBI
Celera151,129,191 - 1,135,694 (+)NCBICelera
Cytogenetic Map15p16NCBI
JBrowse: View Region in Genome Browser (JBrowse)
Model


Disease Annotations     Click to see Annotation Detail View
Acute Lung Injury  (IDA)
adenocarcinoma  (ISO)
adult respiratory distress syndrome  (ISO)
alcoholic liver cirrhosis  (IDA)
Alzheimer's disease  (ISO)
Alzheimer's disease 1  (ISO)
Angina Pectoris  (ISO)
anuria  (ISO)
appendicitis  (ISO)
Arterial Occlusive Diseases  (ISO)
Asthenozoospermia  (IEP,ISO)
asthma  (ISO)
atherosclerosis  (ISO)
Bone Neoplasms  (ISO)
brain edema  (IEP,ISO)
Brain Hypoxia-Ischemia  (IDA,IEP)
brain ischemia  (ISO)
breast cancer  (IDA,ISO)
Cardiomegaly  (IDA)
carotid artery disease  (ISO)
Cerebral Hemorrhage  (ISO)
cerebral infarction  (ISO)
cerebrovascular disease  (ISO)
cholesterol embolism  (ISO)
Chronic Allograft Nephropathy  (ISO)
Chronic Hepatitis C  (ISO)
chronic obstructive pulmonary disease  (IMP,ISO)
Colonic Neoplasms  (ISO)
Coronary Disease  (ISO)
Diabetic Nephropathies  (IEP)
Eczema  (ISO)
end stage renal disease  (IEP,ISO)
Experimental Arthritis  (ISO)
Experimental Liver Cirrhosis  (IDA,IEP,IMP,ISO)
Experimental Mammary Neoplasms  (IMP)
familial hyperlipidemia  (ISO)
fatty liver disease  (ISS)
gliosarcoma  (ISO)
Graft Occlusion, Vascular  (ISO)
Heart Rupture, Post-Infarction  (ISO)
Hematuria  (ISO)
Hemorrhage  (ISO)
Henoch-Schoenlein purpura  (ISO)
hepatitis B  (ISO)
hepatocellular carcinoma  (ISS)
high grade glioma  (ISO)
Hirschsprung's disease  (ISO)
Hyperoxia  (IEP)
Hypotension  (ISO)
idiopathic pulmonary fibrosis  (ISO)
IgA glomerulonephritis  (ISO)
Inflammation  (ISO)
intermediate coronary syndrome  (ISO)
intracranial aneurysm  (ISO)
Intracranial Embolism and Thrombosis  (ISO)
Intracranial Hemorrhages  (IMP,ISO)
ischemia  (ISO)
Jaw Cysts  (ISO)
Kidney Neoplasms  (ISO)
Left Ventricular Hypertrophy  (ISO)
liver cirrhosis  (ISO)
Lung Injury  (IEP)
Lung Neoplasms  (ISO)
lung non-small cell carcinoma  (ISO)
meningitis  (ISO)
middle cerebral artery infarction  (ISO)
mitral valve prolapse  (ISO)
Mouth Neoplasms  (ISO)
myocardial infarction  (IEP,ISO)
Neoplasm Invasiveness  (ISO)
Neoplasm Metastasis  (ISO)
Neoplasm Recurrence, Local  (ISO)
nephritis  (ISO)
Optic Nerve Injuries  (IEP)
oral squamous cell carcinoma  (ISO)
otitis media  (ISO)
pancreatic cancer  (ISO)
Peripheral Nerve Injuries  (IEP)
peritonitis  (ISO)
pleural empyema  (ISO)
prion disease  (ISO)
prostate cancer  (ISO)
Prostatic Neoplasms  (ISO)
pulmonary embolism  (ISO)
pulmonary fibrosis  (IDA,ISO)
Quebec platelet disorder  (ISO)
renal cell carcinoma  (ISO)
renal fibrosis  (ISO)
Reperfusion Injury  (IEP,ISO)
rhinitis  (ISO)
sagittal sinus thrombosis  (ISO)
sciatic neuropathy  (IDA,IEP)
Sepsis  (ISO)
sinusitis  (ISO)
Spinal Cord Injuries  (ISO)
squamous cell carcinoma  (ISO)
status epilepticus  (IDA,IEP,ISO)
Stomach Neoplasms  (ISO)
Stroke  (ISO)
Strongylida Infections  (IMP)
Thromboembolism  (ISO)
thrombosis  (IEP,ISO)
thyroid gland papillary carcinoma  (ISO)
transient cerebral ischemia  (IDA,IEP)
transitional cell carcinoma  (ISO)
Transplant Rejection  (ISO)
urinary bladder cancer  (IDA,ISO)
urolithiasis  (ISO)
Venous Thrombosis  (ISO)
Ventricular Fibrillation  (ISO)
Viral Myocarditis  (ISO)
visual epilepsy  (ISO)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(+)-catechin  (EXP,ISO)
(-)-epigallocatechin 3-gallate  (ISO)
(S)-nicotine  (ISO)
1,1-dichloroethene  (ISO)
1,10-phenanthroline  (ISO)
1,2-dimethylhydrazine  (ISO)
1-naphthyl isothiocyanate  (EXP)
1-octadec-9-enoylglycero-3-phosphate  (ISO)
17beta-estradiol  (ISO)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2-hydroxypropanoic acid  (ISO)
3,3',4,4',5-pentachlorobiphenyl  (ISO)
3,3'-diindolylmethane  (ISO)
3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid  (ISO)
3-isobutyl-1-methyl-7H-xanthine  (ISO)
3-methylcholanthrene  (ISO)
3-phenylprop-2-enal  (ISO)
4,4'-diaminodiphenylmethane  (EXP)
4,4'-sulfonyldiphenol  (ISO)
4-(N-nitrosomethylamino)-1-(3-pyridyl)butan-1-one  (ISO)
5-aza-2'-deoxycytidine  (ISO)
5-fluorouracil  (ISO)
7,12-dimethyltetraphene  (ISO)
acetaldehyde  (EXP)
acetamide  (EXP)
actinomycin D  (ISO)
aflatoxin B1  (ISO)
aldehydo-D-glucose  (ISO)
all-trans-retinoic acid  (ISO)
alpha-D-galactose  (EXP)
amiloride  (ISO)
ammonium chloride  (EXP)
andrographolide  (ISO)
anethole  (ISO)
anthra[1,9-cd]pyrazol-6(2H)-one  (ISO)
antirheumatic drug  (ISO)
aripiprazole  (ISO)
aristolochic acid  (ISO)
arsane  (ISO)
arsenic atom  (ISO)
arsenous acid  (ISO)
atorvastatin calcium  (ISO)
ATP  (ISO)
avobenzone  (ISO)
baicalein  (ISO)
Bardoxolone methyl  (ISO)
belinostat  (ISO)
benazepril  (EXP)
benomyl  (ISO)
benzo[a]pyrene  (ISO)
benzo[b]fluoranthene  (ISO)
beta-naphthoflavone  (ISO)
bis(2-chloroethyl) sulfide  (ISO)
bis(2-ethylhexyl) phthalate  (ISO)
bisdemethoxycurcumin  (ISO)
bisphenol A  (EXP,ISO)
bisphenol F  (ISO)
bleomycin A2  (ISO)
butan-1-ol  (ISO)
cadmium atom  (EXP)
cadmium dichloride  (EXP)
capsaicin  (ISO)
captan  (ISO)
carbamazepine  (ISO)
carbendazim  (ISO)
carbofuran  (EXP)
carbon nanotube  (ISO)
casticin  (ISO)
chlordecone  (ISO)
chloropicrin  (ISO)
choline  (ISO)
chrysin  (ISO)
cisplatin  (EXP,ISO)
clofibric acid  (EXP)
cobalt dichloride  (ISO)
copper atom  (ISO)
copper(0)  (ISO)
copper(II) sulfate  (ISO)
crocidolite asbestos  (ISO)
curcumin  (ISO)
cyclophosphamide  (ISO)
D-glucose  (ISO)
demethoxycurcumin  (ISO)
desferrioxamine B  (ISO)
dexamethasone  (EXP,ISO)
dextran sulfate  (ISO)
diarsenic trioxide  (ISO)
diclofenac  (ISO)
dieckol  (ISO)
dimethylarsinic acid  (ISO)
dinophysistoxin 1  (ISO)
dioxygen  (EXP,ISO)
diuron  (EXP)
dorsomorphin  (ISO)
doxorubicin  (EXP,ISO)
entinostat  (ISO)
ethanol  (EXP,ISO)
etoposide  (ISO)
fenamidone  (ISO)
flavonol  (ISO)
flutamide  (EXP)
folic acid  (ISO)
folpet  (ISO)
furan  (EXP)
galactose  (EXP)
gefitinib  (ISO)
geldanamycin  (ISO)
gemcitabine  (ISO)
Genipin  (ISO)
genistein  (EXP,ISO)
glucose  (ISO)
heparin  (ISO)
hyaluronic acid  (ISO)
ibuprofen  (ISO)
indole-3-methanol  (ISO)
indometacin  (ISO)
iron(III) nitrilotriacetate  (ISO)
isoprenaline  (EXP)
L-methionine  (ISO)
leflunomide  (ISO)
Licochalcone A  (ISO)
lidocaine  (EXP)
lipopolysaccharide  (EXP,ISO)
lithium chloride  (ISO)
lovastatin  (ISO)
LY294002  (ISO)
malathion  (ISO)
mangiferin  (EXP)
medroxyprogesterone acetate  (ISO)
methotrexate  (ISO)
methoxychlor  (EXP)
methylmercury chloride  (ISO)
mitomycin C  (ISO)
N-acetyl-L-cysteine  (ISO)
N-nitrosodiethylamine  (ISO)
N-nitrosodimethylamine  (EXP)
N-tosyl-L-phenylalanyl chloromethyl ketone  (ISO)
nickel atom  (ISO)
nickel sulfate  (ISO)
nicotine  (ISO)
nonanedioic acid  (ISO)
notoginsenoside R1  (ISO)
ornidazole  (EXP)
oxaliplatin  (EXP)
ozone  (EXP,ISO)
panobinostat  (ISO)
paraquat  (EXP)
PD 0325901  (ISO)
pentane-2,3-dione  (EXP)
phenylmercury acetate  (ISO)
phorbol 13-acetate 12-myristate  (ISO)
platycodin D  (EXP)
potassium chromate  (ISO)
progesterone  (ISO)
propanal  (ISO)
pyrrolidine dithiocarbamate  (ISO)
quercetin  (EXP,ISO)
rac-lactic acid  (ISO)
raloxifene  (ISO)
resveratrol  (EXP,ISO)
ryanodine  (ISO)
S-(1,2-dichlorovinyl)-L-cysteine  (ISO)
SB 431542  (ISO)
serpentine asbestos  (ISO)
silibinin  (ISO)
silicon dioxide  (ISO)
silver atom  (ISO)
silver(0)  (ISO)
simvastatin  (ISO)
sodium arsenite  (EXP,ISO)
sodium dichromate  (ISO)
sodium hydroxide  (ISO)
sorafenib  (ISO)
streptozocin  (EXP)
succimer  (ISO)
sulforaphane  (ISO)
sulindac sulfide  (ISO)
sunitinib  (ISO)
tamoxifen  (ISO)
tebuconazole  (ISO)
telmisartan  (EXP)
temozolomide  (ISO)
tetrachloromethane  (EXP,ISO)
thalidomide  (ISO)
thioacetamide  (EXP)
titanium dioxide  (ISO)
topotecan  (EXP)
trans-anethole  (ISO)
trichloroethene  (EXP)
trichostatin A  (ISO)
triclosan  (ISO)
troglitazone  (ISO)
trovafloxacin  (ISO)
tubocurarine  (ISO)
valproic acid  (ISO)
vanadium atom  (ISO)
vanadium(0)  (ISO)
vincaleukoblastine  (ISO)
vorinostat  (ISO)
zinc atom  (ISO)
zinc(0)  (ISO)
zoledronic acid  (ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Cellular Component

Molecular Function

Molecular Pathway Annotations     Click to see Annotation Detail View
Phenotype Annotations     Click to see Annotation Detail View

Mammalian Phenotype
References

References - curated
# Reference Title Reference Citation
1. Antineoplastic effect of iodine in mammary cancer: participation of 6-iodolactone (6-IL) and peroxisome proliferator-activated receptors (PPAR). Aceves C, etal., Mol Cancer. 2009 Jun 6;8:33. doi: 10.1186/1476-4598-8-33.
2. Deleterious effects of plasminogen activators in neonatal cerebral hypoxia-ischemia. Adhami F, etal., Am J Pathol. 2008 Jun;172(6):1704-16. Epub 2008 May 8.
3. Differences in the implantation rates of rat embryos developed in vivo and in vitro: possible role for plasminogen activators. Aflalo ED, etal., Fertil Steril. 2004 Mar;81 Suppl 1:780-5.
4. Therapeutic potential and anti-amyloidosis mechanisms of tert-butylhydroquinone for Alzheimer's disease. Akhter H, etal., J Alzheimers Dis. 2011;26(4):767-78.
5. Association between urokinase haplotypes and outcome from infection-associated acute lung injury. Arcaroli J, etal., Intensive Care Med. 2008 Feb;34(2):300-7. Epub 2007 Nov 10.
6. Activators and inhibitors of the plasminogen system in Alzheimer's disease. Barker R, etal., J Cell Mol Med. 2012 Apr;16(4):865-76. doi: 10.1111/j.1582-4934.2011.01394.x.
7. Transcriptional activation of endothelial cells by TGFbeta coincides with acute microvascular plasticity following focal spinal cord ischaemia/reperfusion injury. Benton RL, etal., ASN Neuro. 2009 Aug 26;1(3). pii: e00015. doi: 10.1042/AN20090008.
8. Urokinase-type plasminogen activator gene therapy in liver cirrhosis is mediated by collagens gene expression down-regulation and up-regulation of MMPs, HGF and VEGF. Bueno M, etal., J Gene Med. 2006 Nov;8(11):1291-9.
9. Protection of cerebral microvasculature after moderate hypothermia following experimental focal cerebral ischemia in mice. Burk J, etal., Brain Res. 2008 Aug 21;1226:248-55. Epub 2008 Jun 16.
10. Both tissue-type plasminogen activator and urokinase prevent intraabdominal abscess formation after surgical treatment of peritonitis in the rat. Buyne OR, etal., Surgery. 2008 Jul;144(1):66-73. Epub 2008 May 21.
11. Whole genome microarray of the major pelvic ganglion after cavernous nerve injury: new insights into molecular profile changes after nerve injury. Calenda G, etal., BJU Int. 2012 May;109(10):1552-64. doi: 10.1111/j.1464-410X.2011.10705.x. Epub 2012 Feb 2.
12. Hepatocyte growth factor (HGF) modulates Leydig cell extracellular matrix components. Catizone A, etal., J Androl. 2010 May-Jun;31(3):306-13. doi: 10.2164/jandrol.109.007658. Epub 2009 Oct 15.
13. Hepatocyte growth factor (HGF) regulates blood-testis barrier (BTB) in adult rats. Catizone A, etal., Mol Cell Endocrinol. 2012 Jan 2;348(1):135-46. doi: 10.1016/j.mce.2011.07.050. Epub 2011 Aug 5.
14. [Effects of Qinggan Huoxue Recipe and its separated recipes on urokinase-type plasminogen activator and plasminogen activator inhibitor-1 fibrinolytic system in rats with alcoholic liver fibrosis]. Chen JM, etal., Zhong Xi Yi Jie He Xue Bao. 2009 Jul;7(7):642-50. doi: 10.3736/jcim20090708.
15. Intravesical administration of plasminogen activator inhibitor type-1 inhibits in vivo bladder tumor invasion and progression. Chen SC, etal., J Urol. 2009 Jan;181(1):336-42. Epub 2008 Nov 17.
16. Lipopolysaccharide upregulates uPA, MMP-2 and MMP-9 via ERK1/2 signaling in H9c2 cardiomyoblast cells. Cheng YC, etal., Mol Cell Biochem. 2009 May;325(1-2):15-23. doi: 10.1007/s11010-008-0016-y. Epub 2009 Jan 28.
17. Neuroprotection by urokinase plasminogen activator in the hippocampus. Cho E, etal., Neurobiol Dis. 2012 Apr;46(1):215-24. Epub 2012 Jan 24.
18. Association between urokinase-plasminogen activator gene T4065C polymorphism and risk of mitral valve prolapse. Chou HT, etal., Int J Cardiol. 2004 Aug;96(2):165-70.
19. Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. Colmenero J, etal., Am J Physiol Gastrointest Liver Physiol. 2009 Oct;297(4):G726-34. Epub 2009 Jul 23.
20. Selective abrogation of the uPA-uPAR interaction in vivo reveals a novel role in suppression of fibrin-associated inflammation. Connolly BM, etal., Blood. 2010 Sep 2;116(9):1593-603. Epub 2010 May 13.
21. No replication of genetic association between candidate polymorphisms and Alzheimer's disease. Cousin E, etal., Neurobiol Aging. 2011 Aug;32(8):1443-51. Epub 2009 Nov 3.
22. Thrombus versus Wall Biological Activities in Experimental Aortic Aneurysms. Coutard M, etal., J Vasc Res. 2009 Dec 16;47(4):355-366.
23. Macrophage-targeted overexpression of urokinase causes accelerated atherosclerosis, coronary artery occlusions, and premature death. Cozen AE, etal., Circulation. 2004 May 4;109(17):2129-35. Epub 2004 Apr 19.
24. Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation. Cunningham O, etal., Glia. 2009 Dec;57(16):1802-14.
25. Urokinase-type plasminogen activator and arthritis progression: contrasting roles in systemic and monoarticular arthritis models. De Nardo CM, etal., Arthritis Res Ther. 2010;12(5):R199. Epub 2010 Oct 25.
26. Impaired fibrinolytic system in ApoE gene-deleted mice with hyperlipidemia augments deep vein thrombosis. Diaz JA, etal., J Vasc Surg. 2012 Mar;55(3):815-22. Epub 2011 Nov 25.
27. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
28. Rat ISS GO annotations from GOA human gene data--August 2006 GOA data from the GO Consortium
29. Effect of dietary beta carotene on cerebral aneurysm and subarachnoid haemorrhage in the brain apo E-/- mice. Gopal K, etal., J Thromb Thrombolysis. 2011 Oct;32(3):343-55.
30. An Antiangiogenic Urokinase-derived Peptide Combined with Tamoxifen Decreases Tumor Growth and Metastasis in a Syngeneic Model of Breast Cancer. Guo Y, etal., Cancer Res 2002 Aug 15;62(16):4678-84.
31. [Effect of amiloride on the pathology of a rat model of chronic obstructive pulmonary disease]. Han XD, etal., Zhonghua Jie He He Hu Xi Za Zhi. 2007 May;30(5):363-7.
32. Partial reversal of established bleomycin-induced pulmonary fibrosis by rh-urokinase in a rat model. Hart DA, etal., Clin Invest Med. 1994 Apr;17(2):69-76.
33. Urokinase-targeted fusion by oncolytic Sendai virus eradicates orthotopic glioblastomas by pronounced synergy with interferon-beta gene. Hasegawa Y, etal., Mol Ther. 2010 Oct;18(10):1778-86. doi: 10.1038/mt.2010.138. Epub 2010 Jul 6.
34. Transcriptional and posttranscriptional activation of urokinase plasminogen activator gene expression in metastatic tumor cells. Henderson BR, etal., Cancer Res 1992 May 1;52(9):2489-96.
35. Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. Heymans S, etal., Am J Pathol. 2005 Jan;166(1):15-25.
36. Fasudil, a Rho-kinase inhibitor, protects against excessive endurance exercise training-induced cardiac hypertrophy, apoptosis and fibrosis in rats. Ho TJ, etal., Eur J Appl Physiol. 2012 Aug;112(8):2943-55. doi: 10.1007/s00421-011-2270-z. Epub 2011 Dec 9.
37. Prognostic role of urokinase-type plasminogen activator in human gliomas. Hsu DW, etal., Am J Pathol. 1995 Jul;147(1):114-23.
38. Tissue-type plasminogen activator depletion affects the nasal mucosa matrix reconstruction in allergic rhinitis mice. Hua H, etal., Allergol Immunopathol (Madr). 2011 Jul-Aug;39(4):206-11. doi: 10.1016/j.aller.2010.09.010. Epub 2011 Feb 19.
39. Gene expression changes of urokinase plasminogen activator and urokinase receptor in rat testes at postnatal stages. Huang DH, etal., Asian J Androl. 2007 Sep;9(5):679-83.
40. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value. Hundsdorfer B, etal., J Craniomaxillofac Surg. 2005 Jun;33(3):191-6. Epub 2005 Apr 22.
41. Urokinase-type plasminogen activator system and human cationic antimicrobial protein 18 in serum and induced sputum of patients with chronic obstructive pulmonary disease. Jiang Y, etal., Respirology. 2010 Aug;15(6):939-46. Epub 2010 Jul 6.
42. Small, potent, and selective diaryl phosphonate inhibitors for urokinase-type plasminogen activator with in vivo antimetastatic properties. Joossens J, etal., J Med Chem. 2007 Dec 27;50(26):6638-46. Epub 2007 Dec 1.
43. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor. Kenichi M, etal., J Lab Clin Med. 2004 Aug;144(2):69-77.
44. Localization of plasminogen activators in human colon cancer by immunoperoxidase staining. Kohga S, etal., Cancer Res. 1985 Apr;45(4):1787-96.
45. [Effects of acupoint-embedment of medicated-thread and acupoint-injection on expression of cortical urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in rats with cerebral ischemia-reperfusion injury]. Kong LH, etal., Zhen Ci Yan Jiu. 2010 Dec;35(6):409-14.
46. Plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in sputum of allergic asthma patients. Kowal K, etal., Folia Histochem Cytobiol. 2008;46(2):193-8.
47. Increased expression and activity of urokinase-type plasminogen activator during epileptogenesis. Lahtinen L, etal., Eur J Neurosci. 2006 Oct;24(7):1935-45. Epub 2006 Oct 16.
48. Urokinase-type plasminogen activator regulates neurodegeneration and neurogenesis but not vascular changes in the mouse hippocampus after status epilepticus. Lahtinen L, etal., Neurobiol Dis. 2010 Mar;37(3):692-703. Epub 2009 Dec 21.
49. Expression of urokinase-type plasminogen activator receptor is increased during epileptogenesis in the rat hippocampus. Lahtinen L, etal., Neuroscience. 2009 Sep 29;163(1):316-28. Epub 2009 Jun 12.
50. Angiostrongylus cantonensis: induction of urokinase-type PA and degradation of type IV collagen in rat lung granulomatous fibrosis. Lan KP and Lai SC, Exp Parasitol. 2008 Apr;118(4):472-7. Epub 2007 Oct 22.
51. [Association of uPA and uPAR expression with invasive behaviors of urinary transitional cell carcinoma]. Li YJ, etal., Ai Zheng. 2004 Jun;23(6):704-6.
52. Norrin attenuates protease-mediated death of transformed retinal ganglion cells. Lin S, etal., Mol Vis. 2009;15:26-37. Epub 2009 Jan 12.
53. Combination therapy of 17beta-estradiol and recombinant tissue plasminogen activator for experimental ischemic stroke. Liu R, etal., J Pharmacol Exp Ther. 2010 Mar;332(3):1006-12. doi: 10.1124/jpet.109.160937. Epub 2009 Dec 1.
54. [Changes of u-PA and PAI-1 expression in the lung tissue of neonatal rats after inhaling high concentration oxygen] Liu XY and Xue XD, Zhonghua Er Ke Za Zhi. 2008 Jun;46(6):458-63.
55. [Correlation of the content and expression of urokinase plasminogen activator with asthenospermia in rat models]. Liu Y, etal., Zhonghua Nan Ke Xue. 2008 Sep;14(9):786-91.
56. Basic mechanisms and regulation of fibrinolysis. Longstaff C and Kolev K, J Thromb Haemost. 2015 Jun;13 Suppl 1:S98-105. doi: 10.1111/jth.12935.
57. Urokinase redistribution from the secreted to the cell-bound fraction in granulosa cells of rat preovulatory follicles. Macchione E, etal., Biol Reprod. 2000 Apr;62(4):895-903.
58. Association of Urokinase Gene 3'-UTR T/C polymorphism with bladder cancer. Manchanda PK, etal., Urol Int. 2006;77(1):81-4.
59. Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overexpressing mice. Matsuo S, etal., Kidney Int. 2005 Jun;67(6):2221-38.
60. Urokinase plasminogen activator stimulates vascular smooth muscle cell proliferation via redox-dependent pathways. Menshikov M, etal., Arterioscler Thromb Vasc Biol. 2006 Apr;26(4):801-7. Epub 2006 Feb 2.
61. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
62. Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer. Miyake H, etal., Int J Oncol. 1999 Mar;14(3):535-41.
63. Downregulation of matrix metalloprotease-9 and urokinase plasminogen activator by TX-1877 results in decreased tumor growth and metastasis on xenograft model of rectal cancer. Miyake K, etal., Cancer Chemother Pharmacol. 2009 Oct;64(5):885-92. doi: 10.1007/s00280-009-0937-5. Epub 2009 Feb 12.
64. Identification of potential biomarkers of lymph node metastasis in oral squamous cell carcinoma by cDNA microarray analysis. Nagata M, etal., Int J Cancer. 2003 Sep 20;106(5):683-9.
65. Partial purification and characterization of epidermal plasminogen activator and their inhibitor. Nakagawa M, etal., Chem Pharm Bull (Tokyo). 1989 Jul;37(7):1859-63.
66. Electronic Transfer of LocusLink and RefSeq Data NCBI rat LocusLink and RefSeq merged data July 26, 2002
67. Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma. Oka T, etal., Cancer Res. 1991 Jul 1;51(13):3522-5.
68. Cell surface-bound plasminogen regulates hepatocyte proliferation through a uPA-dependent mechanism. Okumura N, etal., Biosci Biotechnol Biochem. 2007 Jun;71(6):1542-9.
69. OMIM Disease Annotation Pipeline OMIM Disease Annotation Pipeline
70. Association of urokinase gene 3'-UTR T/C polymorphism with calcium oxalate urolithiasis in children. Ozturk M, etal., Int Urol Nephrol. 2008;40(3):563-8. doi: 10.1007/s11255-008-9335-x. Epub 2008 Feb 1.
71. Blood brain barrier (BBB) dysfunction associated with increased expression of tissue and urokinase plasminogen activators following peripheral thermal injury. Patel TH, etal., Neurosci Lett. 2008 Oct 31;444(3):222-6. Epub 2008 Aug 13.
72. Identification of a novel biomarker signature associated with risk for bone metastasis in patients with renal cell carcinoma. Paule B, etal., Int J Biol Markers. 2010 Apr-Jun;25(2):112-5.
73. Hyperfibrinolysis, uPA/suPAR system, kynurenines, and the prevalence of cardiovascular disease in patients with chronic renal failure on conservative treatment. Pawlak K, etal., Am J Med Sci. 2010 Jan;339(1):5-9.
74. Urokinase-type plasminogen activator and metalloproteinase-2 are independently related to the carotid atherosclerosis in haemodialysis patients. Pawlak K, etal., Thromb Res. 2008;121(4):543-8. Epub 2007 Aug 15.
75. Effects of long-term erythropoietin therapy on fibrinolytic system in haemodialyzed patients. Pawlak K, etal., Thromb Res. 2008;121(6):787-91. Epub 2007 Sep 14.
76. Vascular endothelial growth factor and uPA/suPAR system in early and advanced chronic kidney disease patients: a new link between angiogenesis and hyperfibrinolysis? Pawlak K, etal., Transl Res. 2012 Nov;160(5):346-54. doi: 10.1016/j.trsl.2012.04.004. Epub 2012 May 8.
77. Fraxinus rhynchophylla ethanol extract attenuates carbon tetrachloride-induced liver fibrosis in rats via down-regulating the expressions of uPA, MMP-2, MMP-9 and TIMP-1. Peng WH, etal., J Ethnopharmacol. 2010 Feb 17;127(3):606-13. Epub 2009 Dec 24.
78. Involvement of urokinase-type plasminogen activator in sphingosylphosphorylcholine-induced angiogenesis. Piao YJ, etal., Exp Dermatol. 2005 May;14(5):356-62.
79. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
80. PID Annotation Import Pipeline Pipeline to import Pathway Interaction Database annotations from NCI into RGD
81. Momordica charantia leaf extract suppresses rat prostate cancer progression in vitro and in vivo. Pitchakarn P, etal., Cancer Sci. 2010 Oct;101(10):2234-40. doi: 10.1111/j.1349-7006.2010.01669.x. Epub 2010 Aug 22.
82. Urokinase plasminogen activator in injured adventitia increases the number of myofibroblasts and augments early proliferation. Plekhanova OS, etal., J Vasc Res. 2006;43(5):437-46. Epub 2006 Aug 7.
83. [Effects of shear stress on expression of plasminogen activator (tPA and uPA) in cultured kidney proximal tubular epithelial cells and its significance]. Pu L, etal., Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2008 Dec;25(6):1319-21, 1343.
84. [Effects of losartan on expressions of plasminogen activator and plasminogen activator inhibitor-1 of rat proximal tubular epithelial cells cultured with high glucose]. Pu LJ, etal., Sichuan Da Xue Xue Bao Yi Xue Ban. 2007 Sep;38(5):813-5.
85. Proteins and carbohydrates in nipple aspirate fluid predict the presence of atypia and cancer in women requiring diagnostic breast biopsy. Qin W, etal., BMC Cancer. 2012 Feb 1;12:52. doi: 10.1186/1471-2407-12-52.
86. GOA pipeline RGD automated data pipeline
87. ClinVar Automated Import and Annotation Pipeline RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
88. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
89. Expression of urokinase plasminogen activator and its receptor during acute renal allograft rejection. Roelofs JJ, etal., Kidney Int. 2003 Nov;64(5):1845-53.
90. Role of plasminogen activators during healing after uterine serosal lesioning in the rat. Rout UK and Diamond MP, Fertil Steril 2003 Jan;79(1):138-45.
91. Cerebrospinal fluid u-plasminogen activator and matrix metalloproteinase-9 levels in human eosinophilic meningitis associated with angiostrongyliasis. Sanpool O, etal., Cytokine. 2010 Sep;51(3):294-7. Epub 2010 Jun 26.
92. Plasminogen activator promotes recovery following spinal cord injury. Seeds N, etal., Cell Mol Neurobiol. 2011 Aug;31(6):961-7. Epub 2011 May 14.
93. The expression of fibrinolytic components in chronic paranasal sinus disease. Sejima T, etal., Am J Rhinol Allergy. 2011 Jan-Feb;25(1):1-6.
94. Urokinase and its receptor in follicular and inflammatory cysts of the jaws. Serrati S, etal., Oral Dis. 2010 Nov;16(8):753-9. doi: 10.1111/j.1601-0825.2010.01679.x.
95. Neuron Regeneration and Proliferation Effects of Danshen and Tanshinone IIA. Shen JL, etal., Evid Based Complement Alternat Med. 2011;2011:378907. doi: 10.1155/2011/378907. Epub 2010 Dec 1.
96. Association of polymorphisms in the genes of the urokinase plasminogen activation system with susceptibility to and severity of non-small cell lung cancer. Shih CM, etal., Clin Chim Acta. 2011 Jan 14;412(1-2):194-8. Epub 2010 Oct 16.
97. Inducible lung-specific urokinase expression reduces fibrosis and mortality after lung injury in mice. Sisson TH, etal., Am J Physiol Lung Cell Mol Physiol. 2002 Nov;283(5):L1023-32.
98. Differential regulation of urokinase-type plasminogen activator expression by fluid shear stress in human coronary artery endothelial cells. Sokabe T, etal., Am J Physiol Heart Circ Physiol. 2004 Nov;287(5):H2027-34. Epub 2004 Jul 1.
99. Progress of tissue injury in appendicitis involves the serine proteases uPA and PAI-1. Solberg A, etal., Scand J Gastroenterol. 2009;44(5):579-84.
100. Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues. Span PN, etal., BJU Int. 2008 Jul;102(2):177-82. doi: 10.1111/j.1464-410X.2008.07568.x. Epub 2008 Jul 1.
101. uPA, uPAR and TGFbeta(1) expression during early and late post myocardial infarction period in rat myocardium. Stavropoulou A, etal., In Vivo. 2010 Sep-Oct;24(5):647-52.
102. Evaluation of a pediatric protocol of intrapleural urokinase for pleural empyema: a prospective study. Stefanutti G, etal., Surgery. 2010 Sep;148(3):589-94. Epub 2010 Mar 20.
103. Urokinase plasminogen activator induces smooth muscle cell migration: key role of growth factor-like domain. Stepanova V, etal., FEBS Lett. 1997 Sep 8;414(2):471-4.
104. Osteopontin: a fibrosis-related marker molecule in cardiac remodeling of enterovirus myocarditis in the susceptible host. Szalay G, etal., Circ Res. 2009 Apr 10;104(7):851-9. doi: 10.1161/CIRCRESAHA.109.193805. Epub 2009 Feb 26.
105. Tentative Sequence Identification Numbers Tentative Sequence Data IDs. TIGR Gene Index, Rat Data
106. Matrix metalloproteinase-9 and urokinase plasminogen activator mediate interleukin-1-induced neurotoxicity. Thornton P, etal., Mol Cell Neurosci. 2008 Jan;37(1):135-42. Epub 2007 Sep 12.
107. Confronting complexity in late-onset Alzheimer disease: application of two-stage analysis approach addressing heterogeneity and epistasis. Thornton-Wells TA, etal., Genet Epidemiol. 2008 Apr;32(3):187-203.
108. Mutant prourokinase with adjunctive C1-inhibitor is an effective and safer alternative to tPA in rat stroke. Tomasi S, etal., PLoS One. 2011;6(7):e21999. Epub 2011 Jul 14.
109. Urokinase gene transfer augments angiogenesis in ischemic skeletal and myocardial muscle. Traktuev DO, etal., Mol Ther. 2007 Nov;15(11):1939-46. Epub 2007 Jul 24.
110. Urokinase gene 3'-UTR T/C polymorphism is associated with oral cancer. Tsai MH, etal., J Clin Lab Anal. 2004;18(5):276-9.
111. In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval. Ulisse S, etal., Clin Endocrinol (Oxf). 2012 Nov;77(5):780-6. doi: 10.1111/j.1365-2265.2012.04465.x.
112. Increased stratum corneum serine protease activity in acute eczematous atopic skin. Voegeli R, etal., Br J Dermatol. 2009 Jul;161(1):70-7. Epub 2009 Mar 30.
113. Coexpression of Smad7 and UPA attenuates carbon tetrachloride-induced rat liver fibrosis. Wang B, etal., Med Sci Monit. 2012 Oct;18(10):BR394-401.
114. Inhaled unfractionated heparin improves abnormalities of alveolar coagulation, fibrinolysis and inflammation in endotoxemia-induced lung injury rats. Wang ZY, etal., Chin Med J (Engl). 2013 Jan;126(2):318-24.
115. [Effect of inhalation of aerosolized unfractioned heparin on peri alveolar coagulability and inflammatory response in endotoxin induced acute lung injury rat model]. Wang ZY, etal., Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2011 Apr;23(4):239-42.
116. [Curative machanism of Shenle capsule on 5/6 nephrectomy rats]. Wei RB, etal., Zhongguo Zhong Yao Za Zhi. 2004 Aug;29(8):770-3.
117. Urokinase receptor is necessary for bacterial defense against pneumonia-derived septic melioidosis by facilitating phagocytosis. Wiersinga WJ, etal., J Immunol. 2010 Mar 15;184(6):3079-86. Epub 2010 Feb 8.
118. Expression of urokinase-type plasminogen activator and its receptor is up-regulated during tendon healing. Xia W, etal., J Orthop Res. 2003 Sep;21(5):819-25.
119. Effects of overtraining on skeletal muscle growth and gene expression. Xiao W, etal., Int J Sports Med. 2012 Oct;33(10):846-53. Epub 2012 May 16.
120. Association of putative functional variants in the PLAU gene and the PLAUR gene with myocardial infarction. Xu J, etal., Clin Sci (Lond). 2010 Jul 9;119(8):353-9.
121. [Effects of aerosolized earthworm fibrinolytic enzyme on bleomycin induced pulmonary fibrosis in rats]. Xue Y, etal., Zhonghua Yi Xue Za Zhi. 2012 Dec 25;92(48):3429-33.
122. Possible involvement of urokinase-type plasminogen activator release from human peripheral blood lymphocytes in the pathophysiology of chronic allograft nephropathy. Yamaguchi Y, etal., Transplant Proc. 2005 Dec;37(10):4276-81.
123. Tissue plasminogen activator in primary afferents induces dorsal horn excitability and pain response after peripheral nerve injury. Yamanaka H, etal., Eur J Neurosci. 2004 Jan;19(1):93-102.
124. Therapeutic administration of plasminogen activator inhibitor-1 prevents hypoxic-ischemic brain injury in newborns. Yang D, etal., J Neurosci. 2009 Jul 8;29(27):8669-74.
125. Plasma soluble vascular endothelial growth factor receptor-1 levels predict outcomes of pneumonia-related septic shock patients: a prospective observational study. Yang KY, etal., Crit Care. 2011 Jan 10;15(1):R11.
126. The role and mechanism of the up-regulation of fibrinolytic activity in painful peripheral nerve injury. Yong N and Guoping C, Neurochem Res. 2009 Mar;34(3):587-92. Epub 2008 Aug 21.
127. A novel signaling pathway: fibroblast nicotinic receptor alpha1 binds urokinase and promotes renal fibrosis. Zhang G, etal., J Biol Chem. 2009 Oct 16;284(42):29050-64. doi: 10.1074/jbc.M109.010249. Epub 2009 Aug 18.
128. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B. Zhou H, etal., Thromb Res. 2009;123(3):537-42. Epub 2008 Aug 8.
129. Role of hypoxia-inducible factor-1 alpha in the regulation of plasminogen activator activity in rat knee joint chondrocytes. Zhu G, etal., Osteoarthritis Cartilage. 2009 Nov;17(11):1494-502. doi: 10.1016/j.joca.2009.05.005. Epub 2009 May 19.
130. Differential patterns of local gene regulation in crush lesions of the rat optic and sciatic nerve: relevance to posttraumatic regeneration. Zickler P, etal., Cell Physiol Biochem. 2010;26(3):483-94. Epub 2010 Aug 24.
Additional References at PubMed
PMID:1321734   PMID:8837777   PMID:9733098   PMID:12431485   PMID:12477932   PMID:17382917   PMID:17655862   PMID:17893885   PMID:18481824   PMID:18835034   PMID:19885954   PMID:21423176  
PMID:23376485   PMID:23533145   PMID:23812296   PMID:25168896   PMID:25978044   PMID:26363453   PMID:30671487   PMID:34852179  


Genomics

Comparative Map Data
Plau
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
mRatBN7.2153,456,230 - 3,462,732 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl153,456,232 - 3,462,775 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx153,466,414 - 3,472,916 (-)NCBIRnor_SHR
UTH_Rnor_SHRSP_BbbUtx_1.0154,852,895 - 4,859,397 (-)NCBIRnor_SHRSP
UTH_Rnor_WKY_Bbb_1.0153,465,220 - 3,471,722 (-)NCBIRnor_WKY
Rnor_6.0153,644,296 - 3,650,765 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl153,644,769 - 3,650,819 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.0153,621,057 - 3,627,467 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.4153,680,072 - 3,686,232 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.1153,680,073 - 3,686,275 (-)NCBI
Celera151,129,191 - 1,135,694 (+)NCBICelera
Cytogenetic Map15p16NCBI
PLAU
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCh381073,909,164 - 73,917,494 (+)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p13 Ensembl1073,909,177 - 73,917,496 (+)EnsemblGRCh38hg38GRCh38
GRCh371075,670,890 - 75,677,252 (+)NCBIGRCh37GRCh37hg19GRCh37
Build 361075,340,896 - 75,347,261 (+)NCBINCBI36Build 36hg18NCBI36
Build 341075,340,895 - 75,347,260NCBI
Celera1068,954,178 - 68,960,575 (+)NCBICelera
Cytogenetic Map10q22.2NCBI
HuRef1069,665,797 - 69,672,195 (+)NCBIHuRef
CHM1_11075,952,624 - 75,959,021 (+)NCBICHM1_1
T2T-CHM13v2.01074,782,523 - 74,788,885 (+)NCBIT2T-CHM13v2.0
Plau
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm391420,886,730 - 20,893,456 (+)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl1420,886,728 - 20,893,453 (+)EnsemblGRCm39 Ensembl
GRCm381420,836,662 - 20,843,388 (+)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl1420,836,660 - 20,843,385 (+)EnsemblGRCm38mm10GRCm38
MGSCv371421,655,884 - 21,662,610 (+)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv361419,625,259 - 19,631,940 (+)NCBIMGSCv36mm8
Celera1417,217,270 - 17,223,995 (+)NCBICelera
Cytogenetic Map14A3NCBI
cM Map1411.53NCBI
Plau
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChiLan1.0 EnsemblNW_00495543717,994,537 - 18,000,209 (-)EnsemblChiLan1.0
ChiLan1.0NW_00495543717,995,726 - 18,000,542 (-)NCBIChiLan1.0ChiLan1.0
PLAU
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
PanPan1.11073,104,808 - 73,113,136 (+)NCBIpanpan1.1PanPan1.1panPan2
PanPan1.1 Ensembl1073,105,895 - 73,113,136 (+)Ensemblpanpan1.1panPan2
Mhudiblu_PPA_v01070,433,340 - 70,441,569 (+)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
PLAU
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
CanFam3.1424,329,139 - 24,333,893 (+)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl424,328,925 - 24,334,851 (+)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha424,466,425 - 24,471,181 (+)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.0424,609,212 - 24,613,966 (+)NCBIROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl424,578,978 - 24,727,745 (+)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.1424,506,511 - 24,511,263 (+)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.0424,706,941 - 24,711,694 (+)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.0425,061,896 - 25,066,649 (+)NCBIUU_Cfam_GSD_1.0
Plau
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HiC_Itri_2NW_02440721356,745,370 - 56,751,129 (-)NCBIHiC_Itri_2
SpeTri2.0 EnsemblNW_0049365215,238,093 - 5,243,877 (-)EnsemblSpeTri2.0
SpeTri2.0NW_0049365215,238,128 - 5,243,829 (-)NCBISpeTri2.0SpeTri2.0SpeTri2.0
PLAU
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
Sscrofa11.1 Ensembl1476,629,299 - 76,635,172 (+)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.11476,629,313 - 76,635,173 (+)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.21482,755,642 - 82,761,502 (+)NCBISscrofa10.2Sscrofa10.2susScr3
Pig Cytomap14q24-q26NCBI
PLAU
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChlSab1.1957,452,904 - 57,459,345 (-)NCBIChlSab1.1ChlSab1.1chlSab2
ChlSab1.1 Ensembl957,452,761 - 57,459,286 (-)EnsemblChlSab1.1ChlSab1.1 EnsemblchlSab2
Vero_WHO_p1.0NW_02366604818,028,912 - 18,035,356 (-)NCBIVero_WHO_p1.0Vero_WHO_p1.0
Plau
(Heterocephalus glaber - naked mole-rat)
Naked Mole-rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HetGla_female_1.0 EnsemblNW_0046247547,408,983 - 7,416,559 (+)EnsemblHetGla_female_1.0HetGla_female_1.0 EnsemblhetGla2
HetGla 1.0NW_0046247547,405,637 - 7,415,870 (+)NCBIHetGla_female_1.0HetGla 1.0hetGla2

Variants

.
Variants in Plau
21 total Variants
miRNA Target Status

Predicted Target Of
Summary Value
Count of predictions:67
Count of miRNA genes:55
Interacting mature miRNAs:64
Transcripts:ENSRNOT00000014273
Prediction methods:Miranda, Rnahybrid, Targetscan
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.


QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
1354657Despr13Despair related QTL 130.0022locomotor behavior trait (VT:0001392)amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958)15129912054Rat
8552920Pigfal8Plasma insulin-like growth factor 1 level QTL 83blood insulin-like growth factor amount (VT:0010479)plasma insulin-like growth factor 1 level (CMO:0001299)15134723002Rat
8694361Abfw6Abdominal fat weight QTL 610.20.001visceral adipose mass (VT:0010063)abdominal fat pad weight to body weight ratio (CMO:0000095)15134723002Rat
9589149Insul29Insulin level QTL 299.060.001blood insulin amount (VT:0001560)plasma insulin level (CMO:0000342)15134723002Rat
731170Pur3Proteinuria QTL 32.30.0005urine protein amount (VT:0005160)urine protein excretion rate (CMO:0000759)15141686771Rat
1641887Alcrsp14Alcohol response QTL 14response to alcohol trait (VT:0010489)brain neurotensin receptor 1 density (CMO:0002068)15142356671Rat
2298549Neuinf12Neuroinflammation QTL 123.5nervous system integrity trait (VT:0010566)spinal cord beta-2 microglobulin mRNA level (CMO:0002125)15155302115Rat
10401805Kidm51Kidney mass QTL 51kidney mass (VT:0002707)both kidneys wet weight (CMO:0000085)1530632945306329Rat
5684946Bss98Bone structure and strength QTL 983.90.0026tibia strength trait (VT:1000284)tibia ultimate force (CMO:0001734)15105825014481294Rat
1641913Colcr2Colorectal carcinoma resistance QTL 26.570.0197intestine integrity trait (VT:0010554)colorectal tumor number (CMO:0001794)15226636822711984Rat
1641913Colcr2Colorectal carcinoma resistance QTL 26.570.0197intestine integrity trait (VT:0010554)poorly differentiated malignant colorectal tumor number (CMO:0002076)15226636822711984Rat
738017Hcas7Hepatocarcinoma susceptibility QTL 72.91liver integrity trait (VT:0010547)liver nonremodeling tumorous lesion volume to total liver volume ratio (CMO:0001464)15226636846921453Rat

Markers in Region
AU048556  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2153,461,133 - 3,461,294 (+)MAPPERmRatBN7.2
Rnor_6.0153,649,167 - 3,649,327NCBIRnor6.0
Rnor_5.0153,625,869 - 3,626,029UniSTSRnor5.0
RGSC_v3.4153,684,634 - 3,684,794UniSTSRGSC3.4
Celera151,130,629 - 1,130,791UniSTS
Cytogenetic Map15p16UniSTS
RH94858  
Rat AssemblyChrPosition (strand)SourceJBrowse
Celera151,135,376 - 1,135,600UniSTS
Cytogenetic Map15p16UniSTS
RH94873  
Rat AssemblyChrPosition (strand)SourceJBrowse
Celera151,134,857 - 1,135,067UniSTS
Cytogenetic Map15p16UniSTS
RH136861  
Rat AssemblyChrPosition (strand)SourceJBrowse
Celera151,135,374 - 1,135,578UniSTS
RH 3.4 Map1548.7UniSTS
Cytogenetic Map15p16UniSTS


Expression


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
High
Medium 2 5 3 13 3 8 11 31 33 11 8
Low 1 43 52 38 6 38 67 4 8
Below cutoff 7

Sequence


Reference Sequences
RefSeq Acc Id: ENSRNOT00000014273   ⟹   ENSRNOP00000014273
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl153,456,232 - 3,462,775 (-)Ensembl
Rnor_6.0 Ensembl153,644,769 - 3,650,819 (-)Ensembl
RefSeq Acc Id: ENSRNOT00000097501   ⟹   ENSRNOP00000077608
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl153,456,805 - 3,462,775 (-)Ensembl
RefSeq Acc Id: ENSRNOT00000106260   ⟹   ENSRNOP00000085383
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl153,456,232 - 3,462,355 (-)Ensembl
RefSeq Acc Id: NM_013085   ⟹   NP_037217
RefSeq Status: PROVISIONAL
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2153,456,230 - 3,462,732 (-)NCBI
Rnor_6.0153,644,296 - 3,650,765 (-)NCBI
Rnor_5.0153,621,057 - 3,627,467 (-)NCBI
RGSC_v3.4153,680,072 - 3,686,232 (-)RGD
Celera151,129,191 - 1,135,694 (+)RGD
Sequence:
Reference Sequences
RefSeq Acc Id: NP_037217   ⟸   NM_013085
- Peptide Label: precursor
- UniProtKB: Q3KR76 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: ENSRNOP00000014273   ⟸   ENSRNOT00000014273
RefSeq Acc Id: ENSRNOP00000085383   ⟸   ENSRNOT00000106260
RefSeq Acc Id: ENSRNOP00000077608   ⟸   ENSRNOT00000097501
Protein Domains
EGF-like   Kringle   Peptidase S1

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-P29598-F1-model_v2 AlphaFold P29598 1-432 view protein structure

Transcriptome

eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

Promoters
RGD ID:13699556
Promoter ID:EPDNEW_R10078
Type:single initiation site
Name:Plau_1
Description:plasminogen activator, urokinase
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database, http://epd.vital-it.ch/)
Experiment Methods:Single-end sequencing.
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.0153,650,810 - 3,650,870EPDNEW

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:3343 AgrOrtholog
BioCyc Gene G2FUF-14565 BioCyc
Ensembl Genes ENSRNOG00000010516 Ensembl, ENTREZGENE, UniProtKB/TrEMBL
Ensembl Protein ENSRNOP00000014273 ENTREZGENE
  ENSRNOP00000014273.3 UniProtKB/TrEMBL
  ENSRNOP00000077608.1 UniProtKB/TrEMBL
  ENSRNOP00000085383.1 UniProtKB/TrEMBL
Ensembl Transcript ENSRNOT00000014273 ENTREZGENE
  ENSRNOT00000014273.6 UniProtKB/TrEMBL
  ENSRNOT00000097501.1 UniProtKB/TrEMBL
  ENSRNOT00000106260.1 UniProtKB/TrEMBL
Gene3D-CATH 2.40.10.10 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  2.40.20.10 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
IMAGE_CLONE IMAGE:7456771 IMAGE-MGC_LOAD
InterPro EGF-like_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Kringle UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Kringle-like UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Kringle_CS UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Kringle_sf UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Peptidase_S1_PA UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Peptidase_S1_PA_chymotrypsin UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Peptidase_S1A UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Trypsin_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  TRYPSIN_SER UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Urokinase UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
KEGG Report rno:25619 UniProtKB/TrEMBL
MGC_CLONE MGC:124931 IMAGE-MGC_LOAD
NCBI Gene 25619 ENTREZGENE
PANTHER PTHR24264:SF38 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Pfam Kringle UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Trypsin UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PhenoGen Plau PhenoGen
PRINTS CHYMOTRYPSIN UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PROSITE EGF_1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  EGF_3 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  KRINGLE_1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  KRINGLE_2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  TRYPSIN_DOM UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  TRYPSIN_SER UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
SMART SM00130 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Tryp_SPc UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Superfamily-SCOP SSF50494 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  SSF57440 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
TIGR TC232485
UniProt A0A8I5ZKC2_RAT UniProtKB/TrEMBL
  A0A8I5ZZ41_RAT UniProtKB/TrEMBL
  P29598 ENTREZGENE
  Q3KR76 ENTREZGENE, UniProtKB/TrEMBL
  UROK_RAT UniProtKB/Swiss-Prot
UniProt Secondary Q6LBK5 UniProtKB/Swiss-Prot


Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2002-06-10 Plau  Urinary plasminogen activator, urokinase      Symbol and Name status set to approved 70586 APPROVED

RGD Curation Notes
Note Type Note Reference
gene_cellular_localization secreted as a single chain zymogen with low or no intrinsic enzyme activity 625460
gene_disease expression associated with increased tumor-cell invasion, angiogenesis and metastasis in several malignancies including breast cancer 625460
gene_disease plays a key role in degrading the extracellular matrix and basement membrane in various cancers (such as breast and prostate cancers) 625460
gene_regulation following enzymatic cleavage by plasmin, is converted to the active HMW-uPA comprised of an A-chain and the low molecular-weight uPA which contains the catalytic activity for extracellular matrix degradation 625460